Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02495623 · ClinicalTrials.gov registry record · Phase 2
A Study of the Effect of SYN-010 on Subjects With IBS-C
A Phase 2 study, sponsored by Theriva Biologics.
- Completed
- Registry status
- Phase 2
- Development phase
- 63
- Enrollment target
NCT02495623: Completed Phase 2 study, sponsored by Theriva Biologics.
NCT02495623 is a Phase 2 study that has completed, run by Theriva Biologics. The registered enrollment target is 63 participants, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (53% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02495623, a Phase 2 study, has completed, sponsored by Theriva Biologics.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 63 participants
- Enrollment target
Study Summary
A Randomized, Double-Blind, Parallel-Group, Placebo-Controlled, Multi-Dose Study of the Effect of Two Dosage Strengths of SYN-010 Compared with Placebo on Breath Methane Production in Breath Methane-Positive Subjects with Irritable Bowel Syndrome with Constipation (IBS-C)
Interventions
- DRUG Placebo
- DRUG SYN-010 21 mg
- DRUG SYN-010 42 mg
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 63 participants |
| Start Date | 2015-06 |
| Est. Completion | 2015-11 |
| Phase | Phase 2 |
What the finished NCT02495623 record still lists
NCT02495623 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 63 participants, a relatively small participant target, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (53% lower).
The record links to 0 conditions, and to 3 interventions - of which Placebo is the first listed.
NCT02495623 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT02495623 about?
NCT02495623 is a clinical study titled "A Study of the Effect of SYN-010 on Subjects With IBS-C". A Randomized, Double-Blind, Parallel-Group, Placebo-Controlled, Multi-Dose Study of the Effect of Two Dosage Strengths of SYN-010 Compared with Placebo on Breath Methane Production in Breath Methane-Positive Subjects with Irritable Bowel Syndrome with Constipation (IBS-C)
What is the current status of trial NCT02495623?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 63 participants. The study started on 2015-06. Estimated completion is 2015-11.
What interventions are being tested in trial NCT02495623?
The interventions under investigation include: Placebo (DRUG), SYN-010 21 mg (DRUG), SYN-010 42 mg (DRUG).
Who is sponsoring clinical trial NCT02495623?
This trial is sponsored by Theriva Biologics, which has 7 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT02495623's enrollment target sits among peer trials
63 1009th of 2000 higher than 985 of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03383575 · 63 participants · Phase 2
Azacitidine and Enasidenib in Treating Patients With IDH2-Mutant Myelodysplastic Syndrome
- NCT04870944 · 63 participants · Phase 1
CBL0137 for the Treatment of Relapsed or Refractory Solid Tumors, Including CNS Tumors and Lymphoma
- NCT05031897 · 63 participants · Phase 2
Two Step Haplo With Radiation Conditioning
- NCT05312671 · 63 participants · Phase 2
Atezolizumab Plus Etoposide and Platinum in Small Cell Bladder Cancer
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia